Complete deficiency of complement C4 is among the strongest genetic risk factors for human systemic lupus erythematosus (SLE). C4 is a constituent of the RP-C4-CYP21-TNX (RCCX) module in the human leukocyte antigen (HLA) that exhibits inter-individual copy-number and gene-size variations. Here, we studied two North-African families with complete C4 deficiency and SLE. The first included a Moroccan male SLE patient (1P) and a sibling, who were both homozygous for HLA-A*02 B*17 DRB1*07. The second had an Algerian female SLE patient (2P) homozygous for HLA-A*01 B*17 DRB1*13. Early SLE disease onset, the presence of photosensitive rashes, anti-Ro/SSA, renal disease and high titers of antinuclear antibodies were the common features of complete C4 deficiency. Southern blot analyses showed that 1P had monomodular RCCX with a long C4A, whereas 2P had bimodular RCCX with one long C4A and one short C4B. Genomic DNA fragments for these mutant genes were amplified and sequenced. A C4T transition that created the R540X nonsense mutation in C4A was found in 1P. An identical 4-bp insertion that generated the Y1537X nonsense mutation was discovered in both C4A and C4B of 2P. The high concordance of SLE and C4 deficiency among patients with non-DR3 and non-DR2 haplotypes underscores the importance of C4 proteins in the protection against SLE.
Introduction
The complement system is a group of plasma and membrane proteins that are sequentially activated through proteolytic cleavages to defend against microbial infections. 1, 2 In addition to immune defense, complement components such as C1q, C4 and C3 are important opsonins as they bind to and facilitate the clearance of immune complexes (IC) and apoptotic debris, which would otherwise promote inflammation and autoimmune diseases.
Complete deficiencies of the early complement components including C1q, C1r, C1s and C4 in the classical activation pathway are highly associated with human systemic lupus erythematosus (SLE). 3, 4 SLE is a systemic autoimmune disease characterized by the breakdown of immunotolerance and the production of a wide range of autoantibodies that target multiple tissues and organs. 5, 6 Although the genetic basis for a majority of SLE cases is polygenic, 7, 8 a homozygous deficiency in one of the early complement components alone can be strong enough to cause the disease, a situation similar to a single-gene defect in an autosomal recessive disease. Of the patients with complete C1q and C4 deficiencies, 93 and 78%, respectively, eventually develop SLE or a lupus-like disease. 4, 9 In addition, the concordance rates for siblings with homozygous deficiency of C1q or C4 to develop SLE are 90 and 80%, respectively, which are higher than the rate in monozygotic twins (26-60%) with other genetic defects.
Genetically, the complement C4 gene located in the class III region of the major histocompatibility complex (MHC) on chromosome 6p21.3 shows frequent interindividual copy-number variation (CNV). The C4 CNV is a result of segmental duplications known as RCCX modules. RCCX stands for genes coding for serine/ threonine nuclear protein kinase RP (also known as STK19), complement C4, cytochrome P450 21-hydroxylase CYP21 and extracellular matrix protein tenascin-X TNX. One to four RCCX modules can exist per chromosome 6. [10] [11] [12] [13] In each duplicated module, there is Activated C4B binds rapidly to the hydroxyl group in substrates. Owing to such differences, C4A is believed to be important in the clearances of IC, and C4B is more powerful in propagating the complement activation cascades. The complete absence of both C4A and C4B proteins may therefore lead to decreased ability of immune defense against microbes, as well as inefficient disposal of IC. To date, 28 individuals with complete C4 deficiency from 19 families have been reported. 3, 4, 24 Among them, 15 individuals developed SLE, 7 developed lupus-like diseases, and 4 of the remaining 6 subjects were afflicted by kidney diseases. 24 Multiple complete C4 deficiency subjects also experienced severe or recurrent microbial infections. At least 16 different HLA haplotypes have been found in complete C4 deficiency individuals. Among the complete C4 deficiency cases, the molecular basis of their defects have been elucidated in 12 individuals, but all were of European descent. [25] [26] [27] [28] In this study, we present the clinical features and determine the molecular basis for the complete C4A and C4B deficiencies in two North-African SLE patients.
Results

Case reports
Two unrelated cases of complete C4 deficiency in which the patients developed SLE were studied Case 1. Patient 1P was a Moroccan male born to parents of consanguineous marriage ( Figure 1, panel a) . He was diagnosed with SLE at the age of 6. His clinical presentation included malar rash with marked photosensitivity, chronic discoid lupus erythematosus (DLE) lesions on the lips, hands and feet, positivity for anti-Ro/SSA antibodies, high titers of antinuclear antibodies (1/1280), and renal involvement including moderate proteinuria and microscopic hematuria. Kidney biopsies confirmed the presence of focal proliferative glomerulonephritis with thickening of the capillary walls and a wire loop appearance. Immunofluorescence experiments showed mesangial deposits of IgG and C1q but not C3. Repeated laboratory measurements showed no detectable C4 proteins or CH50 activity, but serum C3 levels were normal. 29 The brother of this patient (1S) shared the same complement abnormalities. He was reported to be healthy until the age of 12. At the age of 17, he presented with repeated infections of the nasal cavity, and a severe sinusitis with infection of the left orbital cavity, which required a surgical intervention. He also presented with microscopic hematuria, but investigations to detect antinuclear antibodies yielded negative results. HLA typing showed that these brothers were homozygous for A*02 B*17 DRB1*07. The complete absence of C4 proteins and CH50 activity but normal C3 protein levels in these brothers suggested a genetic deficiency of complements C4A and C4B. Patient 1P had two other siblings who were heterozygous for the HLA A*02 B*17 DRB1*07 haplotype. The younger sister had relatively low C4 concentration (0.06 g l -1 ) and tested ANA-positive (1/320). Case 2. Patient 2 was an Algerian girl who was among one of the earliest complete C4 deficiency patients reported. 30 She was a child of parents who were married consanguineously ( Figure 1, panel b) . She presented with SLE-related symptoms including lupus erythematous rash, high titers of speckled antinuclear antibodies (1/ 1024), anti-Ro and anti-Sm antibodies, moderate renal disease with mesangial proliferation plus IgM and C1q deposits. The patient also suffered from bacterial meningitides and recurrent lung infections, developed osteomyelitis of the left femur, and eventually died from cardiopulmonary complications at the age of 12. The patient was determined to be homozygous for HLA A*01 B*17 DRB1*13. TaqI restriction fragment length polymorphism (RFLP) analysis with a C4 5 0 probe showed the presence of the 7.0 and 5.4 kb fragments representing the presence of long and short C4 genes. 29, 30 Patient 2P had four siblings, who were all heterozygous for the HLA A*01 B*17 DRB1*13 haplotype, which had no functional C4 genes. All of her siblings tested ANA-positive, with titers ranging from 1/160 to 1/640.
Genotypic characterization of the RCCX modules and C4A and C4B gene copy-numbers and phenotypic characterization of complement proteins Family 1. From TaqI RFLP (Figure 2 , left panel c), patient 1P and one of his siblings 1S shared identical patterns of RCCX with a TaqI restriction fragment of 7.0 kb, corresponding to a long C4 gene, followed by a 3.7-kb restriction fragment for CYP21B and a 2.5-kb restriction fragment for TNXB. This restriction fragment pattern was indicative of a monomodular RCCX containing a single long C4 gene on both the maternal and paternal copies of chromosome 6. The homozygosity of the RCCX was consistent with the homozygous HLA in these two individuals. The same Southern blot for the patient's mother 1M showed three sets of TaqI patterns, each with two restriction fragments of equal intensity: C4L linking to RP1 (7.0 kb) and C4S linking to RP2 (5.4 kb), CYP21B (3.7 kb) and CYP21A (3.2 kb), and TNXB (2.5 kb) and TNXA (2.4 kb). This phenomenon indicated that there were four copies of C4 genes (two of C4L and two of C4S) in the mother's genome. As patient 1P and his sibling 1S inherited a monomodular RCCX from the mother, the only possible interpretation for the mother's other RCCX haplotype was a trimodular configuration with one C4L gene and two C4S genes. PshAI-PvuII RFLP showed that there were no C4B genes for 1P and 1S, with the absence of the 2.2-kb PshAI-PvuII restriction fragment specific for C4B (Figure 2 , left panel d). Equal intensities of bands corresponding to C4A and C4B indicated that 1M had equal numbers of C4A and C4B genes. Thus, the C4 genotypes of the mother were C4L (C4AQ0)/C4L-C4S-C4S (C4A-C4B-C4B). 
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Allotyping of C4 proteins by immunofixation using EDTA-plasma samples from this family showed that there was no trace of C4 proteins for 1P and 1S ( Figure 2 , left panel a). There were three C4 protein variants present in 1M: C4A2, C4B1 and C4B2. However, despite 1M having two copies of C4A genes, the intensity of the C4A2 protein was the same as those for C4B1 and C4B2. In addition, C3 allotyping showed the presence of normal levels of C3 proteins in all three subjects ( Figure 2 , panel b). Such a phenomenon suggests that the absence of C4 proteins in 1P and 1S was unlikely to be a consequence of degradation or consumption of complement proteins. These protein allotyping data were consistent with the constantly undetectable levels of C4 proteins for 1P and 1S by repeated clinical measures.
Given the results from both phenotypic and genotypic analyses, the null allele of C4 was determined to be a single copy of long C4A in a monomodular RCCX linking to HLA A*02 B*17 DRB1*07. Both 1P and 1S were homozygous for this haplotype, and their mother 1M was heterozygous, with monomodular L for a mutant C4A gene, and trimodular LSS coding for C4A2, C4B1 and C4B2, which was linked to HLA A*02 B*14 DRB1*11.
Family 2. TaqI RFLP was performed in patient 2P, her mother 2M and one of her siblings 2S ( Figure 2 , right panel c). In 2P and 2S, we observed the presence of TaqI restriction fragments with equal intensities for the 7.0 and 5.4-kb fragments corresponding to C4L and C4S, respectively; 3.7-and 3.2-kb fragments corresponding to CYP21B and CYP21A, respectively; and 2.5-and 2.4-kb fragments corresponding to TNXB and TNXA, respectively. The patient's mother 2M showed a distinctive 6.4-kb TaqI fragment that is characteristic of a short C4 gene linking to RP1. This 6.4-kb fragment was of the same intensity as the 7.0-kb fragment for RP1-C4L and the 5.4-kb fragment for RP2-C4S. On the other hand, the 3.7-kb fragment for CYP21B was twice that of the 3.2-kb fragment for CYP21A, and the 2.5-kb fragment for TNXB was twice as intense as the 2.4-kb TNXA fragment. Thus, it is concluded that 2M had bimodular long-short (LS) and monomodular-short (S) RCCX haplotypes (LS/S), whereas patients 2P and 2S were both homozygous for LS/LS.
The PshAI-PvuII Southern blot ( Figure 2 , right panel c) showed that the numbers of C4A and C4B genes were the same for 2P and 2S, whereas those of 2M had a ratio of 1:2. Combining the results from the two sets of Southern blots, the RCCX haplotypes for 2M were LS (C4A-C4B) and S (C4B), and those for 2P and her siblings were LS (C4A-C4B)/LS (C4A-C4B).
Stored EDTA-plasma sample from patient 2P was available for complement C4 and C3 protein allotyping experiments. No C4 protein was detectable ( Clinically measurable C4 concentrations were observed in all family members, but were repeatedly undetectable for 2P. With this information, plus the homozygous HLA haplotypes and the consanguineous marriage of her parents, patient 2P was deduced to be homozygous for the bimodular-LS haplotype containing a null allele for C4A and a null allele for C4B, that is, LS (C4AQ0-C4BQ0), linking to HLA-A*01 B*17 DRB1*13.
Screening for the most common C4 and Type I C2 mutation in Family 1 and Family 2 To determine the molecular basis of complete complement C4A and C4B deficiencies, we screened patients 1 and 2 and their family members for the 2-bp insertion at codon 1213 from exon 29 of both C4A and C4B genes. 31 This mutation is relatively common, with a frequency 41% even among healthy subjects of European ancestry. 17 A multiplex sequence-specific primer (SSP)-PCR along with an amplicon to detect the common 28-bp deletion at the exon 6-intron 6 junction of the complement C2 gene was used. None of the members in these two families were positive for the common mutations present in the C4 and C2 genes (Figure 2 , panel e). Negative results in both patients 1 and 2 were also obtained for other known C4 nonsense mutations in exon 13, exon 20 and exon 28 28 (data not shown). Thus, we proceeded to determine the sequence anomalies contributing to the non-expression of C4 proteins in these patients.
A C to T transition in exon 13 of the long C4A gene in HLA-A*2 B*17 DRB1*07 haplotype resulting in a nonsense mutation in codon 540 The long C4A gene from 1P was amplified into five overlapping DNA fragments that ranged from 2.1 to 3.5 kb in length by PCR ( Figure 3, panel a) . Each fragment was sequenced to completion using multiple C4 specific primers in both sense and anti-sense orientations. 16 Sequence comparisons to known C4A gene sequences showed that there were no insertions or deletions in the long C4A gene in 1P. Sequences distinct from that of the C4 reference in the NCBI database (NC_000006.10) SNPs are shown in Table 1 . Of the two novel SNPs, one is a single nucleotide change from G to A at nt-20 055 located in intron 39; the other is a C to T transition at nt-10 142 of codon 540 from exon 13 that replaces an arginine residue with a stop codon.
To verify that the 10 142 C4T (R540X) mutation was not an artifact introduced by PCR but a genuine change in the genomic sequences of 1P, a new SSP PCR RFLP was designed to interrogate genomic DNA samples of 1P and his family members. In this SSP-PCR, an HhaI restriction enzyme cleavage site specifically recognizing the normal C allele at nt-10 142 was introduced during PCR by the reverse primer, resulting in a smaller fragment after HhaI restriction digest and gel electrophoresis. If the T-allele was present instead of the C-allele, this restriction site was not present and the PCR product would be resistant to digestion by HhaI. A single fragment of 159 bp was observed for 1P and 1S, but two fragments, one of 159 bp and the other of 132 bp, were observed for 1M (Figure 3, panel c) . The results confirmed that both 1P and 1S were homozygous for the 10 142 C4T mutation, and that their mother 1M was heterozygous.
An identical 4-bp insertion in exon 36 of the long C4A and short C4B in the HLA-A*01 B*17 DRB1*13 haplotype Patient 2P was homozygous for a bimodular RCCX, with a long C4A mutant gene and a short C4B mutant gene on each copy of her chromosome 6. Using primers specific for the long terminal repeat (LTR) of the endogenous retrovirus HERV-K (C4) in the C4A gene, and for the C4A/C4B isotypic site in exon 26 as anchors, the first 35 exons for the long-C4A gene and for the short-C4B gene were each amplified into three large PCR fragments. A fragment covering from exon 20 to exon 31 and another fragment from exon 35 to the last exon, exon 41, were indiscriminately amplified for both C4A and C4B (Figure 4 , panels b). Direct DNA sequencing of the PCR fragments showed multiple polymorphisms in the coding and non-coding regions (Table 2) . Two novel coding SNPs and two novel intronic SNPs were found. Of the novel coding SNPs, one was a synonymous C to T transition at nt-4659 (codon 661) from exon 16 of the short-C4B genes, whereas the other was a 4bp insertion, GACT, into exon 36 that created frame-shift mutations and changed the tyrosine residue at codon 1537 to a stop codon TGA (Y1537X) (Figure 4 , panel e). The latter was observed in a PCR fragment spanning exons 35-41,
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The C to T transition in the long-C4A gene introduces a premature stop codon Complete complement C4 deficiency and human SLE YL Wu et al which was common for the long-C4A and the short-C4B genes. It was thus essential to determine whether the GACT insertion was present in C4A, C4B or both. Careful examinations of the DNA sequence chromatograms of the 3.6-kb AB2-PCR fragment from patient 2P showed no sign of heterozygosity of this 4-bp insertion (Figure 4 , panel c), suggesting that this mutation was present in both C4A and C4B genes. To eliminate the possibility of an unlikely bias of the PCR for AB2-fragment that selectively amplified one C4 gene but not the other, the same PCR-primer sets were used to amplify genomic regions covering exons 35-41 from DNA samples of the patient's mother (2M) and one of the patient's siblings (2S). Direct DNA sequencing of the PCR fragments from these two family members showed double sequences at the corresponding regions, implying that 2M and 2S were heterozygous for the 4-bp insertion (Figure 4, panel c) . Thus, it was concluded that patient 2P possessed the identical GACT insertions into exon-36 of both C4A and C4B genes. It was also of interest to note that not only the 4-bp insertion to exon 36, but also other polymorphic variants between intron 31 and exon 41 seemed to be identical in the C4A and C4B mutant genes of patient 2P (Table 2) .
A multiplex SSP-PCR combining the Type I C2-mutation screening primers and specific forward primer to recognize the 4-bp insertion in the insertion site and thus amplify the mutant C4 genes was developed to screen for this GACT insertion in the genomic DNA from all members in Family 2. The presence of a 174-bp PCR product indicates the absence of the Type I C2-mutation, as well as the successful amplification of the PCR. The presence of a 79-bp PCR product corresponds to the presence of the 4-bp insertion in C4. The 79-bp fragment was detectable in all family members (Figure 4, panel d) , confirming the presence of the GACT insertion into exon 36 of the C4 genes in the Algerian family.
Discussion
In this study, we have characterized the RCCX structures and elucidated the molecular basis of complete complement C4A and C4B deficiencies in two North-African families. The first case is a Moroccan subject (the parents came from Algeria and their children were born in Morocco) who has homozygous HLA-A*02 B*17 DRB1*07 haplotype with a monomodular RCCX structure containing a single long C4A mutant gene. A C4T mutation at nucleotide 10 142 in exon 13 changed the Arg-540 codon to a stop codon, which was the only molecular defect that knocked out the expression of C4 protein in this patient. By newly designed SSP-PCR and HhaI RFLP analysis, the same mutation was found in the patient's sibling with complete C4 deficiency, and in his mother, who was heterozygous for the HLA-A*02 B*17 DRB1*07 haplotype. Nonsense mutations in exon 13 had been found in two other different HLA haplotypes. One was a 2-bp deletion in codon 497 of a long-C4A mutant gene in HLA A24 Cw7 B38 DR13 with a monomodular RCCX structure. 28 The other is a 1-bp deletion at codon 522 of the short-C4B gene in the HLA A2 B12 DR6 haplotype with a bimodular LS structure containing one long-C4A and one short-C4B mutant genes. 27 Thus, exon 13 seems to be one of the hotspots for C4 mutations ( Figure 5 ).
In the second case, an Algerian girl homozygous with HLA-A*01 B*17 DRB1*13 was found to have both C4A and C4B genes but no C4 proteins. Southern blot analysis showed the presence of one long C4 and one short C4 on each chromosome 6. PshAI-PvuII RFLP showed that both C4A and C4B genes were present. Sequence-specific PCR suggested that the short gene was C4B and therefore the long gene was C4A. PCR amplification and DNA sequencing of specific DNA fragments covering exons 1-35 for C4A, and for C4B, did not show any sequence defects. However, sequencing of the 3.6-kb DNA fragment corresponding to exons 33-41, which was common to both C4A and C4B genes in 2P, showed a GACT insertion in exon 36. Such 4-bp insertion led to frameshift and created the Y1537X nonsense mutation. The homogeneity of the sequencing chromatograms in the patient but not in her mother 2M or sibling 2S (panel c, Figure 4 ), who were heterozygous for HLA A*01 B*17 DRB1*13 and RCCX modules, suggested that the GACT insertion was present in both mutant C4A and C4B genes of 2P. Sequence-specific PCR further confirmed the presence of this insertion in the patient's mother and siblings.
Identical molecular defects in both C4 genes from bimodular RCCX attributed to complete C4 deficiency had been observed in two other HLA haplotypes. One was present in a female Finnish SLE patient who was homozygous for HLA haplotype A2 Cw7 B39 DR15 with LS RCCX modules containing one C4A and one C4B. An identical 2-bp insertion at codon 1213 of exon 29 was present in both the C4A gene and the C4B gene. 26 The other one was present in HLA haplotype A*30 B*18 Mutation responsible for the non-expression of C4 genes. R540X, a mutation changed Arg-540 to a stop codon.
Complete complement C4 deficiency and human SLE YL Wu et al DR*07 with bimodular RCCX modules containing two short C4B genes (SS, C4B-C4B). A G4A mutation at the donor site of intron 28 in both C4B genes probably led to alternative splicing through a cryptic splice site and incorporation of seven additional nucleotides to the transcript and the generation of a stop codon at codon 1208. Such a phenomenon of homogenization of DNA sequences between duplicated genes is intriguing but not uncommon, as we observed considerably high frequencies of bimodular RCCX haplotypes with C4A-C4A or C4B-C4B instead of C4A-C4B configurations among healthy subjects, the presence of CYP21B-CYP21B in bimodular RCCX haplotypes among many Asian Indians, and the presence of two mutant genes Bimodular Long-short (LS) RCCX haplotype with a mutant C4A gene and a mutant C4B gene PCR strategy to amplify the long-C4A and short C4B mutant genes 17, 32, 33 The complete deficiencies of complements C4A and C4B serve as natural 'knock-out' models yielding insights into the function of C4 proteins. The pathological consequence for the complete absence of C4 protein highlights its importance in microbial defense, as most C4-deficient subjects experienced recurrent infections. Another important outcome in most complete C4 deficiency subjects is the onset of SLE or immunecomplex-related diseases, irrespective of the HLA DR3 or DR2 haplotypes that have been linked to SLE. 34, 35 Twenty-two out of 28 patients with complete C4 deficiency from 16 different HLA haplotypes developed SLE or lupus-like diseases, and 4 others had renal diseases including glomerulonephritis. 4 Inefficient clearance immune complexes caused by genetic C4 deficiencies is a likely etiologic mechanism that promotes inflammatory and autoimmune conditions. Among the complete C4 deficiency patients who developed SLE, Sequence variations from the reference human C4 sequence in the GenBank are shown. Novel sequence variations found in this work are listed in bold; changes which were also found in other C4 polymorphic variants are shown in normal font; the polymorphic or mutant nucleotide sequence within a codon is italicized. there are also common features that include early disease onset, severe photosensitive skin lesions, and the presence of anti-Ro/SSA and high titers of antinuclear antibodies. 4 The prevalence of anti-Ro/SSA is of particular interest, as they are among the earliest autoantibodies detectable in sera and before manifestations of SLE clinical criterion or diagnosis. 36 It has been observed that anti-Ro is associated with neonatal lupus, photosensitive rash, subacute cutaneous lupus erythematosus and Sjogren's syndrome. 37 Whether the genetic and/or acquired deficiency of complement C4 plays a role in initiating the generation of anti-Ro has not been investigated.
Systemic lupus erythematosus is a complex disease that requires both genetic risk factors and environmental triggers such as hormonal fluctuations and infections. The average female-to-male ratio in SLE is approximately 9:1. However, such a female dominance effect, which is at least in part contributed by female hormones, is completely masked by the condition of complete C4 deficiency. Complete C4 deficiency patients developed SLE with a female-to-male ratio of 1:1 and most developed the disease before puberty. The higher susceptibility of these individuals to infections potentially lowers the threshold to trigger the autoimmune disease. Although rare in prevalence in human populations, clinical presentations in subjects of complete complement C4 deficiency underscore the importance of C4 proteins in the protection against SLE. Such a notion is reiterated in mouse complement C4 knockout AT gag Figure 5 A summary of known deleterious mutations in the long and short C4 genes leading to C4A and/or C4B deficiencies. The locations of the earlier determined mutations 28 are marked by } and those determined in this study are marked by asterisks. The mutations, associated HLA and RCCX haplotypes as well as the mutant C4A or C4B containing the defects are listed below the exon-intron structures.
Complete complement C4 deficiency and human SLE YL Wu et al models that showed an impaired humoral immune response, high prevalence in the generation of antinuclear antibodies, anti-double-stranded DNA antibodies and glomerulonephritis. 38, 39 In humans, common inter-individual CNV of C4 genes leads to the generation of two isotypes of polymorphic proteins, C4A and C4B, and a quantitative trait in plasma C4 protein concentrations ranging from 10 to 70 mg dl -1 (that is, 0.1-0.7 g l -1
). 33, 40, 41 The low gene copy-number of C4A has been shown to be strongly associated with SLE in human subjects of European ancestry. 17 Thus, the absence or the low expression of complement C4 or, more specifically, C4A seems to be an important genetic risk factor for SLE. Among the SLE patients, concurrent consumptions or fluctuations of plasma protein levels for C4 and C3, as well as the deposition of C4 inactivation product C4d on erythrocytes, are relevant biomarkers for SLE disease activities. [41] [42] [43] Although genetic deficiency of complement C4 is a probable causative factor for SLE disease pathogenesis, transient or acquired phenotypic deficiency of serum/plasma C4 proteins has been thought to be a result of SLE disease activity. We propose that human subjects with low total C4 or C4A gene copynumber would be more likely to experience transient C4 protein deficiency under an acute infection or other pathogenic conditions, which could trigger aberrant immune responses and initiate a path cumulating in autoimmune diseases. The observations of antinuclear antibodies in multiple members of Families 1 and 2 ( Figure 1 ), who had low copy-numbers or the absence of functional C4A and/or C4B genes, are in keeping with the notion for a link between the quantitative variation of human C4 and immunotolerance or autoimmunity.
Materials and methods
Genomic DNA samples and plasma samples DNA samples were prepared from peripheral blood lymphocytes from frozen blood samples of subjects of Family 1 and patient 2P using a commercial DNA isolation kit (Puregene, Gentra Systems/QIAGEN, Valencia, CA, USA) following the manufacturer's instructions. DNA samples for subjects 2S and 2M of Family 2 were prepared from frozen blood samples using a Blood and Cell culture DNA Maxi kit (QIAGEN).
Determination of complement protein allotypes
Complement C4A and C4B protein allotypes were determined by immunofixation after standard protocol, 44 using EDTA-plasma samples stored at -80 1C. Briefly, 4-6 ml of neat plasma was diluted to a final volume of 8 ml with 1 Â phosphate-buffered saline (PBS). Samples were digested by neuraminidase overnight at 4 1C to remove post-translational irregularities caused by glycosylation on complement C4 proteins, 45 followed by digestion with carboxypeptidase B for 30 min at room temperature to eliminate heterogeneities caused by incomplete proteolytic processing of the b-and a-chain carboxyl termini of the three-chain polypeptide structures. 46 Digested proteins were subjected to high-voltage gel electrophoresis, and then to immunofixation with goat anti-human C4 polyclonal antibodies (DiaSorin, Stillwater, MN, USA). After multiple blottings and washings, gels were stained with SimplyBlue Safestain (Invitrogen, Carlsbad, CA, USA) for the visualization of C4 protein allotypes. Complement C3F (fast) and C3S (slow) protein allotypes were determined similarly, except that five times less of plasma samples and goat anti-human C3 polyclonal antibodies were used.
Genomic RFLP to determine RCCX modular variations and copy-number of C4A and C4B genes Two genomic RFLP and Southern blot analyses were employed to determine the RCCX modular variations and copy-numbers of C4A and C4B genes. Genomic DNA samples from studied subjects were digested by TaqI restriction enzyme and resolved by agarose gel electrophoresis as described earlier. 44 After hybridization with RP-, CYP21-and TNX-specific probes and autoradiography, the relative intensities of the bands were quantified. Along with specific patterns, the numbers of long and short C4 genes that linked to RP1 and RP2, as well as the ratio of CYP21B to CYP21A genes and the ratio of the TNXB genes to TNXA gene fragments were determined. The relative copy-numbers of C4A and C4B genes were determined by PshAI-PvuII Southern blot. After hybridization using a probe specific to the C4d region in both C4A and C4B genes, the relative band intensity yielded the ratio of C4A to C4B. Together with TaqI RFLP, which elucidated the total number of C4 genes, the individual numbers of C4A and C4B genes were determined.
PCR amplification and sequencing of C4 genes 1P. The long C4A gene was amplified into five overlapping DNA fragments (Fragments A-E) with sizes ranging from 2.1 to 3.5 kb by polymerase chain reaction (PCR) (Figure 3, panel a) . PCR primers for human C4 were designed on the basis of published sequences. 14, 16 Fragment A spanning exons 1-9 was amplified by primers E1.5 (that is, primers corresponding to the 5 0 end of exon 1) and E9.3 (that is, reverse primer corresponding to the 3 0 end of exon 9). Skipping the endogenous retroviral element in intron 9, HERV-K(C4), Fragment B spanning exons 10-21 was amplified by primers E10. 5 2P. Three overlapping fragments specific for the long-C4A genes were amplified (Figure 4 , left panel b): Fragment A1, covering the first nine exons, was amplified using a forward primer (RPIN7F) that anchored at intron 7 of the RP gene and a reverse primer (C4L-3LTR-R) that anchored at the 3 0 LTR of HERV-K(C4). Fragment A2 spanning exons 10-21 was amplified using primers C4E10.5 and C4A-up, which was specific for the C4A isotypic site in exon 26. Fragment A3, covering from the C4A isotypic site to exon 35, was amplified using primers C4A-down and E35.3.
Similarly, three large fragments specific for the short C4B genes were generated (Figure 4 , right panel b): Fragment B1, covering up to the first 10 exons, was amplified using primers RPIN7F and E10.3. Fragment B2 spanning from intron 9 to the isotypic site for C4B in exon 26 was amplified using primers C4Fin95 and C4B-up. Fragment B3 spanning from the C4B isotypic site through exon 35 was amplified using primers C4B-down and E35.3.
Two common fragments from both the long-C4A genes and the short-C4B genes were amplified: Primers E20.5 and E31.3 were used to amplify exons 20-31 (Fragment AB1), and primers E33.5 and E41.3 were used to amplify exons 33-41 (Fragment AB2) of the long-C4A gene and short-C4B gene indiscriminately.
All PCRs were carried out using the Failsafe PCR System (Epicentre Technologies, Madison, WI, USA). PCR cycles were 94 1C for 2 min followed by 33 to 36 cycles at 94 1C for 45 s, 58 1C for 45 s and 72 1C for 3 min, and one step at 72 1C for 10 min. PCR fragments were subjected to sequencing reaction using C4-specific primers and the ABI Big Dye v3.1 kit (Part No.: 4336917, Warrington, UK). Sequencing products were purified using a gel filtration cartridge (Cat No.: 42453) from EDGE Biosystems (Gaithersburg, MD, USA) and analyzed using the 3130 Â l Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) operated by the sequencing core at the Research Institute at Nationwide Children's Hospital. Sequences were aligned to a short-C4B gene (AL049547) using Lasergene SeqMan v7.0 (DNASTAR Inc., Madison, WI, USA). Novel changes were defined as those not found in dbSNP Build 129 (http://www.ncbi.nlm.nih.gov/SNP) or in the published literature. 16, 19, 47 Sequence-specific primer (SSP-) PCR to screen complement C2 and C4 mutations in the genomic sequences 2-bp insertion in exon 29 of C4 and Type I C2 mutations. A multiplex SSP-PCR was developed earlier to screen for the most common C4 mutation, a 2-bp insertion in codon 1213 from exon 29, and the type I C2 mutation, a 28-bp deletion in the junction of exon 6 and intron 6. 48 Primers C4E26.5 and C4E29insR were used to amplify the mutated C4 gene. Primers 5C2 and 3C2 were used to amplify the C2 exon 6-intron 6 junction. PCR cycles were 94 1C for 3 min followed by 30 cycles at 94 1C for 30 s, 60 1C for 1 min and 72 1C for 1 min, and one step at 72 1C for 10 min.
C to T mutation in exon 13 of C4. For the C to T mutation, primers E13-FY1 and E13-RY2 were used to amplify exon 13 with a thermal cycle of 94 1C for 3 min followed by 35 cycles at 94 1C for 30 s, 59 1C for 1 min and 72 1C for 2 min, and one step at 72 1C for 5 min. PCR product was subjected to digestion by HhaI enzyme. In the presence of the normal C allele the PCR fragment will be subjected to enzymatic digestion, whereas in the presence of the mutant T allele the PCR fragment will not be cut.
4-bp insertion in exon 36 of C4. The 4-bp insertion in exon 36 was screened by PCR using primers 4 bp-InsF2 and 4 bp-InsR1 with PCR cycles of 94 1C for 3 min followed by 35 cycles at 94 1C for 30 s, 57 1C for 1 min and 72 1C for 1 min, and one step at 72 1C for 5 min. Primers 5C2 and 3C2 were also added in the reaction mix as positive amplification control.
The Failsafe PCR System (Epicentre Technologies, Madison, WI, USA) was used for all three SSP-PCR assays. PCR products were resolved by gel electrophoresis. Specific sequences of PCR primers are listed in Supplementary Table 1. 
